KFDA Approves Phase III Clinical Trial for Aropotin

TS Corporation announced on April 6th that the Korea Food and Drug Administration (KFDA) has approved the phase III clinical trial for Aropotin, an independently developed, bioengineered treatment for the anemia associated with chronic renal failure in patients with reduced kidney function or on hemodialysis.

Aropotin belongs to a class of erythropoietin (EPO) based biopharmaceutical, with t...